Pacific Edge shares fall 63% after Novitas decision

Pacific Edge shares fall 63% after Novitas decision
(Image: Pacific Edge)
Rebecca Howard
Cancer diagnostics company Pacific Edge has come out swinging against a decision by Novitas, the Medicare administrative contractor with jurisdiction for its US laboratory, that would end reimbursement for Cxbladder Triage, Detect and Monitor. The shares fell 63% to $0.050 in early trading Monday after a trading halt was lifted.According to Pacific Edge, Novitas continues to misunderstand the current standard of care in evaluating hematuria patients, fails to consider new peer-reviewed evidence and repeats its flawed analysis of the existi...

More Markets

Brokers reveal top NZX picks for 2026
Markets

Brokers reveal top NZX picks for 2026

Billions shifting from term deposits could boost NZX heavyweights and recovery plays.

Why Rakon’s $390m takeover failed
Markets Best of BusinessDesk

Why Rakon’s $390m takeover failed

The Skyworks deal collapsed in 2024. Now, another deal is on the table.

Business confidence boost uninspired NZ sharemarket
Markets Market Close

Business confidence boost uninspired NZ sharemarket

The S&P/NZX 50 Index closed at 13,656.05, down 27.24 points or 0.2%.

Graham Skellern 13 Jan 2026
Fletcher's residential unit records fewer profitable completions
Markets

Fletcher's residential unit records fewer profitable completions

Light building product volumes look positive, heavy volumes weigh on second quarter.